Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036124 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,744
- Enrollment target
NCT03036124 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 4,744 participants.
The verdict
NCT03036124, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,744 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,744 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03036124
The ClinicalTrials.gov registry entry for NCT03036124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03036124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03036124 about?
NCT03036124 is a clinical study titled "Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure". The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
What is the current status of trial NCT03036124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,744 participants. The study started on 2017-02-08. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT03036124?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT03036124?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.